Senovia Biosciences
The most powerful therapeutic variable in medicine is the one no one is designing for.
What you already know
These are some of the most successful therapies of the last two decades.
Each one was designed to do one thing. Each one turned out to do far more than anyone expected.
Metformin
Approved for type 2 diabetes.
Now in clinical trials for cancer, Alzheimer’s, aging, and cardiovascular disease. A glucose drug with benefits across 10+ disease areas. No single-target explanation accounts for this.
GLP-1 receptor agonists
Approved for diabetes and obesity.
Showing benefits in NASH, heart failure, Alzheimer’s, addiction, and Parkinson’s. Semaglutide alone is in 50+ trials for non-metabolic indications. These drugs are doing something upstream.
SGLT2 inhibitors
Approved for diabetes.
In DAPA-HF and EMPEROR-Reduced, 40% of patients had no diabetes. Glucose reduction was negligible (HbA1c: 0.16–0.20%). Yet cardiovascular mortality dropped 25–26%. The benefit comes from somewhere other than the designed mechanism.
The ketogenic diet
Not a drug. A metabolic state.
Achieves 55% seizure reduction in drug-resistant epilepsy (Cochrane 2020), outperforming 9 of 11 approved medications. First used in 1921. No pharmaceutical replicates the state it produces.
Every one of these works by shifting metabolic state.
None of them were designed to.
We're building the first generation that is.
The pattern
It isn't just in the drugs. It's in the diseases.
Across seemingly unrelated conditions, the same upstream variable keeps appearing.
Alzheimer’s Disease
Cerebral glucose hypometabolism appears on FDG-PET imaging 20+ years before symptoms (Reiman et al., PNAS 2004). Anti-amyloid drugs clear amyloid equally across patient groups but produce divergent clinical benefit. The brain is energy-starved before plaques accumulate.
Heart Failure
SGLT2 inhibitors reduce cardiovascular mortality by 25–26% in heart failure patients without diabetes, with negligible glucose reduction. The consistent pharmacological signal: elevated ketone bodies. The benefit follows the metabolic shift, not the designed mechanism.
Cancer
55–81% of patients don’t respond to checkpoint inhibitors. Patients with higher metabolic reserve show 28–51% better survival on immunotherapy across six independent meta-analyses. T-cells exhaust in a metabolically hostile tumor microenvironment.
Epilepsy
30% of patients fail every available medication. The ketogenic diet achieves 55% responder rates in this population (Cochrane 2020) at 1/15th the cost of the average anti-seizure drug. The metabolic intervention outperforms the pharmaceuticals.
Psychiatry
Treatment-resistant schizophrenia shows 46% PANSS reduction with metabolic intervention (Danan et al., 2022). PET imaging reveals glucose hypometabolism across seven psychiatric conditions. The metabolic deficit mirrors what we see in neurodegeneration.
Autoimmune Disease
Published clinical remission in treatment-resistant ulcerative colitis through metabolic intervention. Seven validated anti-inflammatory pathways engaged simultaneously. Single-target biologics plateau at 30–40% endoscopic remission.
Six diseases. Six separate fields. One recurring observation.
The therapeutic variable is metabolic state.
A different model for drug response
What changes when you add metabolic state to the equation.
From
The drug failed.
To
Right target, wrong metabolic context.
From
Patients share a disease.
To
Patients share a diagnosis, not a metabolic state.
From
Drug response variability is noise.
To
Drug response variability reflects metabolic state.
From
Dose determines efficacy.
To
Dose × metabolic capacity determines efficacy.
From
Drug + drug.
To
Drug + metabolic state optimization.
Each of these reframes is supported by published data across multiple therapeutic areas. The pattern is consistent, directional, and biologically grounded.
What we see
Medicine already knows that metabolic state matters.
The evidence is across every therapeutic area. In the drugs that outperform their labels. In the diseases that resist every targeted approach. In the dietary interventions that succeed where pharmaceuticals fail.
What's missing is the pharmacology.
No oral medicine exists that can reliably achieve, sustain, and titrate a defined metabolic state for chronic therapeutic use — without dietary restriction, with pharmaceutical-grade precision, at scale. That's what a state actuator is. And that's what Senovia is building.
A different way of thinking about disease.
Target-First Medicine
Metabolic State Medicine
Pipeline
Seven programs. One platform.
Each program applies the same insight to a different disease where bioenergetic dysfunction is a demonstrated upstream driver.
The science
Built on published evidence.
Selected findings from the peer-reviewed literature that inform our approach.
Anti-amyloid drugs clear amyloid equivalently across APOE4 genotypes, but clinical benefit diverges by 2–4x based on brain metabolic status.
Evans et al., Alzheimer’s & Dementia 2023
Overweight patients show 28–51% better survival on checkpoint inhibitors across six independent meta-analyses totaling >10,000 patients.
McQuade et al., Lancet Oncol 2018; Cortellini et al., J Immunother Cancer 2019
SGLT2 inhibitors reduce cardiovascular mortality by 25–26% in patients without diabetes, with negligible glucose reduction. Ketone body elevation is the consistent signal.
McMurray et al., NEJM 2019 (DAPA-HF); Inagaki et al., Clin Ther 2018
The ketogenic diet achieves a 55% responder rate in drug-resistant epilepsy, outperforming 9 of 11 approved anti-seizure medications.
Cochrane Systematic Review 2020
If metabolic state is a variable in drug response, it changes how you design trials, select patients, and interpret failures.
We'd like to talk about what that means for your pipeline.